In the latest trading session,, 1.22 million ImmunityBio Inc (NASDAQ:IBRX) shares changed hands as the company’s beta touched -0.01. With the company’s most recent per share price at $2.73 changing hands around $0.03 or 1.11% at last look, the market valuation stands at $2.41B. IBRX’s current price is a discount, trading about -173.99% off its 52-week high of $7.48. The share price had its 52-week low at $1.83, which suggests the last value was 32.97% up since then. When we look at ImmunityBio Inc’s average trading volume, we note the 10-day average is 8.36 million shares, with the 3-month average coming to 9.34 million.
Analysts gave the ImmunityBio Inc (IBRX) stock a consensus recommendation rating of Sell, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 1 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IBRX as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Instantly IBRX is in green as seen in intraday trades today. With action -1.09%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -59.68%, with the 5-day performance at -1.09% in the red. However, in the 30-day time frame, ImmunityBio Inc (NASDAQ:IBRX) is 5.00% up. Looking at the short shares, we see there were 72.36 million shares sold at short interest cover period of 6.6 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 54.5% from its recent market value. According to analyst projections, IBRX’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -119.78% plunge from its current level, while the stock would need to soar -119.78% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 2.39%. The 2025 estimates are for ImmunityBio Inc earnings to increase by 23.85%.
IBRX Dividends
ImmunityBio Inc is expected to release its next quarterly earnings report on 2025-May-12.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 74.11% of ImmunityBio Inc shares while 9.24% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 35.68%. There are 9.24% institutions holding the ImmunityBio Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 2.0135% of the shares, roughly 13.83 million IBRX shares worth $87.42 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 1.6629% or 11.42 million shares worth $72.19 million as of 2024-06-30.
